Cognitive correlates of hypothalamic-pituitary-adrenal axis in major depression

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 1, 2011, Pages 109-126

  Schlosser, Nicole ^a   Wolf, Oliver T ^b   Wingenfeld, Katja ^c  

^a Department of Psychiatry and Psychotherapy   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

amygdala; cognition; cortisol; hippocampus; HPA axis; human; major depressive disorder; memory; pharmacotherapy; psychotherapy

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; DESIPRAMINE; ESCITALOPRAM; FLUDROCORTISONE; FLUOXETINE; HYDROCORTISONE; IMIPRAMINE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MONOAMINE OXIDASE INHIBITOR; NELIVAPTAN; PRASTERONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; ZIMELDINE;

COGNITION; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; COGNITIVE DEFECT; COGNITIVE THERAPY; CORRELATION ANALYSIS; ENVIRONMENTAL EXPOSURE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; META ANALYSIS (TOPIC); PATHOGENESIS; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SOCIAL PSYCHOLOGY;

EID: 78650500922     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.79     Document Type: Review

References (152)

1. Joels M, Karst H, DeRijk R, de Kloet ER. The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 31(1), 1-7 (2007).
2. Roozendaal B, Hernandez A, Cabrera SM et al. Membrane-associated glucocorticoid activity is necessary for modulation of long-term memory via chromatin modification. J. Neurosci. 30(14), 5037-5046 (2010).
3. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J. Psychiatr. Res. 34, 383-392 (2000).
4. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6(6), 463-475 (2005).
5. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J. Psychiatry Neurosci. 29(3), 185-193 (2004).
6. Burke HM, Davis MC, Otte C, Mohr DC. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 30, 846-865 (2005).
7. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2). N. Engl. J. Med. 319(7), 413-420 (1988).
8. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 31, 464-468 (2008).
9. Bhagwagar Z, Hafizi S, Cowen PJ. Increased salivary cortisol after waking in depression. Psychopharmacology (Berl.) 183(1), 54-57 (2005).
10. Vreeburg SA, Hoogendijk WJG, van Pelt J et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity - results from a large cohort study. Arch. Gen. Psychiatry 66(6), 617-626 (2009).
11. Holsboer F. The corticosteroid receptor hypothesis of depression. NeuroPsychopharmacology 23(5), 477-501 (2000).
12. Strickland PL, Deakin JF, Percival C, Dixon J, Gater RA, Goldberg DP. Bio-social origins of depression in the community - interactions between social adversity, cortisol and serotonin neurotransmission. Br. J. Psychiatry 180, 168-173 (2002).
13. Wong ML, Kling MA, Munson, PJ et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl Acad. Sci. USA 97(1), 325-330 (2000).
14. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7, 254-275 (2002).
15. Gold PW, Calabrese JR, Kling MA et al. Abnormal ACTH and cortisol responses to ovine corticotropin releasing factor in patients with primary affective disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 10(1), 57-65 (1986).
16. Holsboer F, Gerken A, von Bardeleben U et al. Human corticotropin- releasing hormone in depression - correlation with thyrotropin secretion following thyrotropin-releasing hormone. Biol. Psychiatry 21(7), 601-611 (1986).
17. Carroll BJ. Dexamethasone suppression test for depression. In: Frontiers in Biochemical and Pharmacological Research in Depression (Volume 39). Usdin E. (Ed.). Raven Press, NY, USA, 179-188 (1984).
18. Appelhof BC, Huyser J, Verweij M et al. Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol. Psychiatry 59, 696-701 (2006).
19. Nemeroff CB, Evans DL. Correlation between the dexamethasone suppression test in depressed patients and clinical response. Am. J. Psychiatry 141(2), 247-249 (1984).
20. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J. Psychiatr. Res. 35, 83-94 (2001).
21. Ising M, Horstmann S, Kloiber S et al. Combinded dexamethasone/ corticotrophin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol. Psychiatry 62, 47-54 (2007).
22. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry. 60, 24-28 (2003).
23. Pariante CM, Papadopoulos AS, Poon L et al. A novel prednisolone suppression test for the hypothalamic-pituitary- adrenal axis. Biol. Psychiatry 51, 922-930 (2002).
24. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl.) 189, 225-235 (2006).
25. Juruena MF, Pariante CM, Papadopoulos A, Cleare AJ. The development and application of the prednisolone suppression test in psychiatry: a novel tool for assessing glucocorticoid and mineralocorticoid receptor function. Mind & Brain, J. Psych. 1(1), 115-122 (2010).
26. Nemeroff CB, Widerlov E, Bisette G et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226, 1342-1343 (1984).
27. Calfa G, Kademian S, Ceschin D, Vega G, Rabinovich GA, Volosin M. Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment. Psychoneuroendocrinology 28, 687-701 (2003).
28. Webster MJ, Knable MB, O'Grady J, Orthmann J, Weickert CS. Regional specifity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol. Psychiatry 7, 985-994 (2002).
29. Ranga K, Krishnan R, Doraiswamy PM et al. Pituitary size in depression. J. Clin. Endocrinol. Metab. 72, 256-259 (1991).
30. Nemeroff CB, Krishnan KRR, Reed D, Leder R, Beam C, Dunnick R. Adrenal gland enlargement in major depression. Arch. Gen. Psychiatry. 49, 384-387 (1992).
31. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 19(3), 269-301 (1988).
32. De Kloet ER, DeRijk RH, Meijer OC. Therapy insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat. Clin. Pract. Endocrinol. Metab. 3(2), 168-179 (2007).
33. Van Rossum EFC, Binder EB, Majer M et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry 59, 681-688 (2006).
34. Otte C, Wüst S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA. Glucocorticoid receptor gene and depression in patients with coronary heart disease: the heart and soul study - 2009 Curt Richter Award Winner. Psychoneuroendocrinology 34(10), 1574-1581 (2009).
35. Kuningas M, de Rijk RH, Westendorp RG, Jolles J, Slagboom PE, van Heemst D. Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. NeuroPsychopharmacology 32, 1295-1301 (2007).
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. American Psychiatric Publishing, Washington, DC, USA (1994).
37. Beblo T, Lautenbacher S. [Neuropsychology of depression]. Hogrefe, Göttingen, Germany (2006).
38. Chamberlain SR, Sahakian BJ. The neuropsychology of mood disorders. Curr. Psychiatry Rep. 8, 458-463 (2006).
39. Porter RJ, Bourke C, Gallagher P. Neuropsychological impairment in major depression: its nature, origin and clinical significance. Aust. NZ J. Psychiatry 41, 115-128 (2007).
40. Christensen H, Griffiths K, Mackinnon A, Jacomb P. A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J. Int. Neuropsychol. Soc. 3(6), 631-651 (1997).
41. Leppanen JM. Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr. Opin Psychiatry 19(1), 34-39 (2006).
42. Henry J, Crawford JR. A meta-analytic review of verbal fluency deficits in depression. J. Clin. Exp. Neuropsychol. 27(1), 78-101 (2005).
43. Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am. J. Psychiatry 165(6), 731-739 (2008).
44. Williams JMG, Barnhofer T, Crane C et al. Autobiographical memory specifity and emotional disorder. Psychol. Bull. 133(1), 122-148 (2007).
45. Gualtieri CT, Johnson LG. Age-related cognitive decline in patients with mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(4), 962-967 (2008).
46. Douglas KM, Porter R J. Longitudinal assessment of neuropsychological function in major depression. Aust. NZ J. Psychiatry 43(12), 1105-1117 (2009).
47. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 213(1-2), 93-118 (2008).
48. Lorenzetti V, Allen NB, Fornito A, Yucel M. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J. Affect. Disord. 117(1-2), 1-17 (2009).
49. de Kloet ER, Oitzl MS, Joels M. Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci. 22(10), 422-426 (1999).
50. Belanoff JK, Gross K, Yager A, Schatzberg AF. Corticosteroids and cognition. J. Psychatr. Res. 35, 127-145 (2001).
51. de Quervain DJF, Aerni A, Schelling G, Roozendaal B. Glucocorticoids and the regulation of memory in health and disease. Front. Neuroendocrinol. 30, 358-370 (2008).
52. Het S, Ramlow G, Wolf OT. A meta-analytic review of the effects of acute cortisol administration on human memory. Psychoneuroendocrinology 30, 771-784 (2005).
53. Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE. The effects of stress and stress hormones on human cognition: implications for the field of brain and cognition. Brain Cogn. 65, 209-237 (2007).
54. Sandi C, Pinelo-Nava MT. Stress and memory: behavioural effects and neurobiological mechanisms. Neural Plast. 1-20 (2007).
55. Joels M, Pu Z, Wiegert O, Oitzl MS, Krugers HJ. Learning under stress: how does it work? Trends Cogn. Sci. 10, 152-158 (2006).
56. Roozendaal B. Stress and memory: opposing effects of glucocorticoids on memory consolidation and memory retrieval. Neurobiol. Learn. Mem. 78, 578-595 (2002).
57. Wolf OT. Stress and memory in humans: twelve years of progress? Brain Res. 1293, 142-154 (2009).
58. Wolf OT. The influence of stress hormones on emotional memory: relevance for psychopathology. Acta Psychol. (Amst.) 127(3), 513-531 (2008).
59. Tulving E. Organization of memory: quo vadis? In: The Cognitive Neurosciences. Gazzangia MS (Ed.). MIT Press, Cambridge, UK, 839-847 (1995).
60. Baddeley A. Working memory. Science 255, 556-559 (1992).
61. Newcomer JW, Sella H, Melson AK. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch. Gen. Psychiatry 56, 527-533 (1999).
62. Newcomer JW, Craft S, Hershey T, Askins K, Bardgett ME. Glucocorticoid-induced impairment in declarative memory performance in adult humans. J. Neurosci. 14(4), 2047-2053 (1994).
63. Kirschbaum C, Wolf OT, May M, Wippich W, Hellhammer DH. Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. Life Sciences 58(17), 1475-1483 (1996).
64. Wolf OT, Convit A, McHugh PF et al. Cortisol differentially affects memory in young and elderly men. Behav. Neurosci. 115(5), 1002-1011 (2001).
65. Buchanan TW, Lovallo WR. Enhanced memory for emotional material following stress-level cortisol treatment in humans. Psychoneuroendocrinology 26, 307-317 (2001).
66. Cahill L, Gorski L, Le K. Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at encoding. Learn. Mem. 10, 270-274 (2003).
67. Kuhlmann S, Wolf OT. Arousal and cortisol interact in modulating memory consolidation in healthy young men. Behav. Neurosci. 120, 217-223 (2006).
68. Abercrombie HC, Kalin NH, Thurow ME, Rosenkranz MA, Davidson RJ. Cortisol variation in humans affects memory for emotionally laden and neutral information. Behav. Neurosci. 117, 505-516 (2003).
69. Rimmele U, Domes G, Mathiak K, Hautzinger M. Cortisol has different effects on human memory for emotional and neutral stimuli. Neuroreport 14, 2485-2488 (2003).
70. Lupien S, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav. Neurosci. 113(3), 420-430 (1999).
71. Young AH, Sahakian BJ, Robbins TW. The effects of chronic administration of hydrocortisone on cognitive function in normal volunteers. Psychopharmacology 145, 260-266 (1999).
72. Schoofs D, Preuss D, Wolf OT. Psychosocial stress induces working memory impairments in an n-back paradigm. Psychoneuroendocrinology 33, 643-653 (2008).
73. Kuhlmann S, Kirschbaum C, Wolf OT. Effects of oral cortisol treatment in healthy young women on memory retrieval of negative and neutral words. Neurobiol. Learn. Mem. 83, 158-162 (2005).
74. Kuhlmann S, Piel M, Wolf OT. Impaired memory retrieval after psychosocial stress in healthy young men. J. Neurosci. 25 (11), 2977-2982 (2005).
75. Buss C, Wolf OT, Witt J, Hellhammer DH. Autobiographic memory impairment following acute cortisol administration. Psychoneuroendocrinology 29, 1093-1096 (2004).
76. Roozendaal B, Okuda S, de Quervain DJ, McGaugh JL. Glucocorticoids interact with emotion-induced noradrenergic activation in influencing different memory functions. Neuroscience 138, 901-910 (2006).
77. Pavlides C, Watanabe Y, McEwen BS. Effects of glucocorticoids on hippocampal long-term potentiation. Hippocampus 3, 183-192 (1993).
78. de Quervain DJ, Henke K, Aerni A et al. Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. Eur. J. Neurosci. 17, 1296-1302 (2003).
79. Oei NYL, Elzinga BM, Wolf OT et al. Glucocorticoids decrease hippocampal and prefrontal activation during declarative memory retrieval in young men. Brain Imaging Behav. 1, 31-41 (2007).
80. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46-56 (2008).
81. Herbert J, Goodyer IM, Grossman AB et al. Do corticosteroids damage the brain? J. Neuroendocrinol. 18, 393-411 (2006).
82. Vythilingam M, Heim C, Newport J et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am. J. Psychiatry 159(12), 2072-2080 (2002).
83. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with major depression. J. Neurosci. 19, 5034-5043 (1999).
84. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc. Natl Acad. Sci. USA 93(9), 3908-3913 (1996).
85. Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast. 737-754 (2007).
86. Becker S, Macqueen G, Wojtowicz JM. Computational modeling and empirical studies of hippocampal neurogenesis-dependent memory: effects of interference, stress and depression. Brain Res. 1299, 45-54 (2009).
87. Kelly WF, Checkley SA, Bender DA, Mashiter K. Cushing's syndrome and depression - a prospective study of 26 patients. Br. J. Psychiatry 142, 16-19 (1983).
88. Starkman MN, Giordani B, Berent S, Schork MA, Schteingart DE. Elevated cortisol levels in Cushing's disease are associated with cognitive decrements. Psychosom. Med. 63, 985-993 (2001).
89. Bremner JD, Vythilingam M, Vermetten E, Anderson G, Newcomer JW, Charney DS. Effects of glucocorticoids on declarative memory function in major depression. Biol. Psychiatry 55, 811-815 (2004).
90. Schlosser N, Wolf OT, Carvalho Fernando S et al. Effects of acute cortisol administration on autobiographical memory in patients with major depression and healthy controls. Psychoneuroendocrinology 35, 316-320 (2010).
91. Rubinow DR, Post RM, Savard R, Gold PW. Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen. Psychiatry 41, 279-283 (1984).
92. Wauthy J, Ansseau M, von Frenckell R, Mormont C, Legros JJ. Memory disturbances and dexamethasone suppression test in major depression. Biol. Psychiatry 30, 736-738 (1991).
93. Sikes CR, Stokes PE, Lasley BJ. Cognitive sequelae of hypothalamic-pituitary-adrenal (HPA) dysregulation in depression. Biol. Psychiatry 25, 148A-152A (1989).
94. Egeland J, Lund A, Landro NI et al. Cortisol level predicts executive and memory function in depression, symptom level predicts psychomotor speed. Acta Psychiatr. Scand. 112, 434-441 (2005).
95. Gomez R, Fleming SH, Keller J et al. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol. Psychiatry 60, 472-478 (2006).
96. van Londen L, Goekoop JG, Zwindermann AH, Lanser JBK, Wiegant VM, de Wied D. Neuropsychological performance and plasma cortisol, arginine vasopressin and oxytocin in patients with major depression. Psychol. Med. 28, 275-284 (1998).
97. Michopoulos I, Zervas IM, Pantelis C et al. Neuropsychological and hypothalamic- pituitary-axis function in female patients with melancholic and non-melancholic depression. Eur. Arch. Psychiatry Clin. Neurosci. 258, 217-225 (2008).
98. Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg, AF. Cortisol activity and cognitive changes in psychotic major depression. Am. J. Psychiatry 158, 1612-1616 (2001).
99. Barnhofer T, Kuehn EM, de Jong-Meyer R. Specifity of autobiographical memories and basal cortisol levels in patients with major depression. Psychoneuroendocrinology 30, 403-411 (2005).
100. den Hartog HM, Nicolson NA, Derix MMA, van Bemmel AL, Kremer B, Jolles J. Salivary cortisol patterns and cognitive speed in major depression: a comparison with allergic rhinitis and healthy control subjects. Biol. Psychol. 63, 1-14 (2003).
101. Gomez RG, Posener JA, Keller J, DeBattista C, Solvason B, Schatzberg AF. Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. Psychoneuroendocrinology 34, 1012-1018 (2009).
102. Hinkelmann K, Moritz S, Botzenhardt J et al. Cognitive impairment in major depression: association with salivary cortisol. Biol. Psychiatry 66, 879-885 (2009).
103. Mannie ZN, Barnes J, Bristow GC, Harmer CJ, Cowen PJ. Memory impairment in young women at increased risk of depression: influence of cortisol and 5-HTT genotype. Psychol. Med. 39, 757-762 (2009).
104. Holsboer F, Lauer CJ, Schreiber W, Krieg JC. Altered hypothalamic- pituitary- adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 62, 340-347 (1995).
105. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18, 253-262 (1998).
106. Vythilingam M, Vermetten E, Anderson GM et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol. Psychiatry 56, 101-112 (2004).
107. Brown WA, Qualls CB. Pituitary-adrenal disinhibition in depression: marker of a subtype with characteristic clinical features and response to treatment? Psychiatr. Res. 4, 115-128 (1981).
108. Winokur G, Black DW, Nasrallah A. DST nonsuppressor status: relationship to specific aspects of the depressive syndrome. Biol. Psychiatry 22, 360-368 (1987).
109. Caine ED, Yerevanian BI, Bamford KA. Cognitive function and the dexamethasone suppression test in depression. Am. J. Psychiatry 141, 116-118 (1984).
110. Wolkowitz OM, Reus VI, Weingartner H et al. Cognitive effects of corticosteroids. Am. J. Psychiatry 147, 1297-1303 (1990).
111. Zobel AW, Schulze-Rauschenbach S, von Widdern OC et al. Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment. J. Psychiatr. Res. 38, 377-383 (2004).
112. Reppermund S, Zihl J, Lucae S. Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary- adrenocortical (HPA) system regulation. Biol. Psychiatry 62, 400-406 (2007).
113. Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br. J. Psychiatry 194(4), 342-349 (2009).
114. Kaufmann J, Charney D. Effects of early stress on brain structure and function: implications for understanding the relationship between child maltreatment and depression. Dev. Psychopathol. 13, 451-471 (2001).
115. Hammen CL. Stress and depression. In: Annual Review of Clinical Psychiatry (Volume 1). Annual Reviews, Palo Alto, CA, USA, 293-319 (2005).
116. Monroe SM, Hadjiyannakis KL. The social environment and depression: focusing on severe life stress. In: Handbook of Depression. Gotlib IH, Hammen CL (Eds). Guilford Press, NY, USA, 314-340 (2002).
117. Starkman MN, Schteingart DE, Schork MA. Cushing's syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res. 19, 177-188 (1986).
118. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Neurosci. 7, 137-151 (2006).
119. Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress. Anxiety 26, 641-649 (2009).
120. Porter RJ, Gallagher P. Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments. Acta Neuropsychiatrica 18, 193-209 (2006).
121. Schüle C, Baghai TC, Eser D, Rupprecht R. Hypothalamic-pituitary- adrenocortical system dysregulation and new treatment strategies in depression. Expert Rev. Neurother. 9(7), 1005-1019 (2009).
122. Thomson F, Craighead M. Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33, 691-707 (2008).
123. Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst. Rev. 1, CD005168 (2008).
124. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29, 1538-1545 (2004).
125. Mason BL, Pariante CM. The effects of antidepressants on the hypothalamic- pituitary-adrenal axis. Drug News Perspect. 19(10), 603-608 (2006).
126. Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol. 19, 213-226 (2006).
127. Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J. Clin. Invest. 87, 831-837 (1991).
128. Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 55, 621-626 (1992).
129. Reul JM, Stee I, Soder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic- pituitary- adrenocortical system. Endocrinology 133, 312-320 (1993).
130. Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F. Hypothalamic- pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60, 509-519 (1994).
131. Yau JL, Olsson T, Morris RG, Meaney MJ, Seckl JR. Glucocorticoids, hippocampal corticoid receptor gene expression and antidepressant treatment: relationship with spatial learning in young and aged rats. Neuroscience 66, 571-581 (1995).
132. Carvalho LA, Pariante CM. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress 11(6), 411-424 (2008).
133. Otte C, Hinkelmann K, Moritz S. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double blind, placebo-controlled proof-of-concept study. J. Psychiatr. Res. 44(6), 339-346 (2010).
134. Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS. Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J. Psychopharmacol. 23, 985-987 (2009).
135. López JF, Chalmers DT, Little KY, Watson SJ. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 43, 547-573 (1998).
136. McKay MS, Zakzanis KK. The impact of treatment on HPA axis activity in unipolar major depression. J. Psychiatr. Res. 44, 183-192 (2010).
137. Young EA, Abelson JL, Cameron OG. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol. Psychiatry 56, 113-120 (2004).
138. Watson S, Gallagher P, Del-Estal D, Hearn A, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol. Med. 32, 1021-1028 (2002).
139. Nemeroff CB, Heim CM, Thase ME et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. PNAS 100(24), 14293-14296 (2003).
140. Heim C, Plotsky PM, Nemeroff CB. Importance of studying the contributions of adverse early experience to neurobiological findings in depression. Neuropsychopharmacology 29, 641-648 (2004).
141. Heim C, Mletzko T, Purselle D, Musselman DL, Nemeroff CB. The dexamethasone/corticotrophin-releasing factor test in men with major depression: role of childhood trauma. Biol. Psychiatry 63(4), 398-405 (2008).
142. Adam EK, Hawkley LC, Kudielka BM, Cacioppo JT. Day-to-day dynamics of experience cortisol associations in a population-based sample of older adults. Proc. Natl Acad. Sci. USA 103, 17058-17063 (2006).
143. Adam EK, Sutton JM, Doane LD, Mineka S. Incorporating hypothalamic- pituitary-adrenal axis measures into preventive interventions for adolescent depression: are we there yet? Dev. Psychopathol. 20, 975-1001 (2008).
144. Hawley LL, Ho MHR, Zuroff DC, Blatt SJ. Stress reactivity following brief treatment for depression: differential effects of psychotherapy and medication. J. Consult. Clin. Psychol. 75(2), 244-256 (2007).
145. Thase ME, Dubé S, Bowler K et al. Hypothalamic-pituitary- adrenocortical acitivity and response to cognitive behaviour therapy in unmedicated, hospitalized depressed patients. Am. J. Psychiatry 153 (7), 886-891 (1996).
146. Schwabe L, Wolf OT. Stress prompts habit behavior in humans. J. Neurosci. 29(22), 7191-7198 (2009).
147. Yang TT, Hsiao FH, Wang KC et al. The effect of psychotherapy added to pharmacotherapy on cortisol responses in outpatients with major depressive disorder. J. Nerv. Ment. Dis. 197 (6), 401-406 (2009).
148. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol. Psychiatry 54, 1389-1398 (2003).
149. Kirschbaum C, Klauer T, Filipp SH, Hellhammer DH. Sex-specific effects of social support on cortisol and subjective responses to acute psychosocial stress. Psychosom. Med. 57, 23-31 (1995).
150. Gaab J, Blattler N, Menzi T, Pabst B, Stoyer S, Ehlert U. Randomized controlled evaluation of the effects of cognitive-behavioral stress management on cortisol responses to acute stress in healthy subjects. Psychoneuroendocrinology 28, 767-779 (2003).
151. Hammerfald K, Eberle C, Grau M, Kinsperger A, Zimmermann A, Ehlert U. Persistent effects of cognitive-behavioral stress management on cortisol responses to acute stress in healthy subjects - a randomized controlled trial. Psychoneuroendocrinology 31, 333-339 (2006).
152. Ursin H, Erikson HR. The cognitive activation theory of stress. Psychoneuroendocrinology 29, 567-592 (2004).